Vita-Salute San Raffaele University-founded Genenta has now assembled $35.4m altogether to progress gene therapies for cancer targeting haematopoietic stem and progenitor cells.
Genenta, an Italy-based oncological gene therapy exploiting research from Vita-Salute San Raffaele University, has increased its latest round to €15.1m ($16.6m) with $2.1m from unnamed new and existing investors including individuals and family offices, StartupBusiness reported on Monday.
The extension follows an initial $14.5m tranche in September 2019 co-led by private equity firm Qianzhan Investment Management and family office Fidim.
Genenta is working on therapies for cancer that deposit genetic material into haematopoietic stem and progenitor cells to…
